GE HealthCare is pursuing a $1 billion acquisition of Sofie Biosciences to grow its diagnostics division, while GSK is partnering with research entities to access healthcare data for 88 million residents in the Greater Bay Area. Meanwhile, Novo Nordisk faces pressure as Morgan Stanley downgraded its stock due to patent risks, and secret drugmaker deals threaten to cut projected Medicare pricing savings by up to 80%. Additionally, Sun Pharma settled a U.S. generic drug pricing lawsuit for an undisclosed sum.
01Opportunity signal
GE HealthCare in Talks to Acquire Sofie Biosciences for $1 Billion
Securing in-house production of short-lived radiopharmaceuticals eliminates supply-chain bottlenecks for molecular imaging equipment makers, shifting competition from hardware design to proprietary diagnostic tracer access.
GE HealthCare is in talks to acquire radiopharmaceutical developer Sofie Biosciences for $1 billion. The potential transaction would give the medical imaging manufacturer full ownership of Sofie, which is currently backed by firm Trilantic Partners and counts Jubilant Pharma among its stakeholders. Trilantic previously valued Sofie at $550 million when it acquired a nearly 26 percent stake in 2024. The would expand GE HealthCare's pharmaceutical diagnostics division, a segment that generated $2.9 billion in last year and supplies agents used in scans alongside its existing MRI, CT, and PET equipment. This follows GE HealthCare's $2.3 billion agreement in March to buy software provider Intelerad, marking its second major deal since its 2023 from General Electric. A formal announcement could arrive as soon as next week.
Novo Nordisk Rebrands to 'Novo' and Announces Corporate Changes
Losing dominance in the injectable obesity market forces a reliance on oral formulations where manufacturing scalability and earlier commercial launch dictate the next phase of market share.
cnbc.com reports that Novo Nordisk is rebranding to "Novo" and updating its corporate culture while battling for obesity against Eli Lilly. The Danish drugmaker is maintaining Novo Nordisk as its legal name, a title originating from the 1989 of Novo Terapeutisk Laboratorium and Nordisk Insulinlaboratorium. Shares of Novo have dropped about 15% this year following the cancellation of three trials for an experimental cardiovascular drug. Meanwhile, the company held a 38.8% market share in the obesity space during the second quarter compared to Eli Lilly's 60.9%, according to data cited from a Lilly presentation. Despite these headwinds, the oral version of Wegovy surpassed 3 million prescriptions by June and secured a head start over Lilly's rival pill, Foundayo. Novo plans to outline further strategic changes at its Markets Day event on Sept. 21.
Q2 Obesity Market Share (%)
Novo trails Eli Lilly in the obesity drug space during the second quarter
GSK to use Greater Bay Area data to improve healthcare policy
Pharma companies can now monetize regulatory evidence from real-world patient populations only through formal data-sharing partnerships, making academic and government institutions gatekeepers of drug development economics.
scmp.com reports that GSK is using patient data from the 88 million residents of the Greater Bay Area to accelerate drug development in vaccines and . GSK Hong Kong and Macau general manager Nicholas Teo stated that the regional data serves as supplementary evidence for regulatory filings and label expansions. The pharmaceutical company signed a memorandum of understanding in September last year with the University of Hong Kong and the Greater Bay Area International Institute to examine the long-term health effects of the shingles vaccine. GSK is providing financial sponsorship for the study and investing in shared data infrastructure. Pharmaceutical companies cannot access the hospital and government data directly without such partnerships. The Greater Bay Area encompasses 11 cities with a combined gross domestic product exceeding US$2.23 trillion last year.
Novo Nordisk Downgraded by Morgan Stanley Over Semaglutide Patent Risk
Semaglutide's impending patent cliff exposes the fragility of a mono-product growth model when next-generation oral formulations fail to offer sufficient revenue replacement.
Morgan Stanley downgraded Novo Nordisk to Underweight from Equal-weight on September 11, setting a 250 Danish kroner price target or about $40 on the New York listing. Analyst Thibault Boutherin cited concentration risk as the core vulnerability, with semaglutide expected to generate roughly 75% of group sales in 2026. The drug faces a starting in 2031 in Europe and 2032 in the United States, exposing the company to generic competition that the oral obesity pipeline cannot fully offset. Novo Nordisk previously guided to full-year sales and operating profit growth of flat to minus 6% at constant exchange rates. fell to 78.2% from 82.7% a year earlier in the second quarter, while Wegovy injection sales dropped 22%.
Gross Margin (%)
Gross margin fell by 4.5 percentage points year-over-year in the second quarter.
Analysis Suggests Secretive Trump Pharma Deals May Impact Pricing Rules
Exempting individual manufacturers through side agreements undermines the benchmark model, shifting Medicare pricing power back to drugmaker negotiations rather than international price tracking.
Secretive deals cut with more than two dozen pharmaceutical companies may slash the projected savings of a Trump administration drug-pricing plan by as much as 80%, statnews.com reports. The initiative relies on a most-favored nation approach to tie drug prices to what 19 other wealthy nations pay for the same medicines. The White House previously projected the effort would save Medicare $26 billion over several years. To execute the policy, the administration is launching the GLOBE and GUARD pilot programs for Medicare Part B and Part D, which mandate additional rebates if drug prices exceed the lowest international benchmarks.
Sun Pharma Settles US Generic Drug Pricing Antitrust Lawsuit
Resolving legacy U.S. price-fixing liabilities eliminates a tail-risk overhang for Sun Pharma, shifting investor focus back to core generic pricing dynamics and specialty pipeline execution.
Sun Pharmaceutical Industries has settled its role in the Pennsylvania-based In re Generic Pharmaceuticals Pricing Litigation for an undisclosed sum. The agreement covers subsidiaries including Sun Pharmaceutical Industries Inc., Taro Pharmaceutical Industries Ltd, and Taro Pharmaceuticals U.S.A. Inc., securing a full release of all claims without an admission of liability or wrongdoing. Shares of Sun Pharmaceutical Industries Ltd fell 1.18 percent to close at ₹1,842.00 on the BSE following the announcement. The resolution closes a legacy U.S. legal dispute for the drugmaker while keeping financial terms and other specific conditions confidential.
Pharmaceutical companies are aggressively expanding diagnostic capabilities and data access while managing heavy legal and patent risks. Whether regulatory changes and shifting market share will erode long-term profitability across top-tier drugmakers remains unresolved.
This, every morning.
SuMarket writes Healthcare and Pharmaceutical Sector every morning, along with every other section of the market and the companies and topics you follow. Free to read.